Loading...
XSHE
000153
Market cap358mUSD
Jul 10, Last price  
5.49CNY
1D
4.97%
1Q
-17.81%
Jan 2017
-57.41%
IPO
-35.18%
Name

Anhui Fengyuan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000153 chart
P/E
25.66
P/S
0.66
EPS
0.21
Div Yield, %
1.91%
Shrs. gr., 5y
1.24%
Rev. gr., 5y
1.10%
Revenues
3.86b
-9.95%
873,807,853955,695,4751,074,181,7771,516,487,7431,657,764,5111,529,898,1141,698,945,4191,569,410,0062,033,683,3952,578,105,4363,013,395,3633,238,064,4363,321,182,3643,501,668,7423,652,216,7364,004,020,3814,004,020,3814,275,436,7134,284,620,5813,858,212,108
Net income
99m
-38.19%
14,183,56822,986,18541,625,5199,913,12319,018,89727,346,62840,990,92235,179,62545,836,29365,348,14760,926,37880,921,048103,720,161122,983,675122,983,676154,426,589154,426,592159,285,570160,834,82799,415,904
CFO
119m
-5.50%
36,268,69155,259,46749,822,55932,405,22955,037,40755,063,47145,650,433010,510,49745,498,59978,211,86652,395,110233,592,50466,213,294292,753,328237,881,716439,990,375254,751,792126,235,149119,297,762
Dividend
May 30, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Hefei, China in 1997, Anhui Fengyuan Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of a wide array of medicinal products. The company primarily serves the Chinese market, offering biological pharmaceuticals, chemical drugs, and traditional Chinese medicines. Its extensive product portfolio addresses numerous health concerns, including pain and fever relief, cardiovascular conditions, infections, neurological disorders, cancer, ulcers, and hormonal imbalances. Fengyuan Pharmaceutical also produces nutritional supplements, treatments for vitamin and mineral deficiencies, anti-parasitic and antimicrobial agents, coenzymes, antiviral medications, and uterine contractants. Furthermore, its offerings encompass sedative-hypnotics, drugs for irritable bowel syndrome, hypertension treatments, and remedies for benign prostatic hyperplasia. Beyond its domestic operations, the company exports its pharmaceutical goods to international markets such as Europe, North America, Africa, Southeast Asia, and Central Asia.
IPO date
Sep 20, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT